RPRX Royalty Pharma plc

Price (delayed)

$35.43

Market cap

$21.51B

P/E Ratio

354.3

Dividend/share

$0.77

EPS

$0.1

Enterprise value

$26.92B

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals ...

Highlights
The company's quick ratio has shrunk by 87% YoY but it rose by 6% QoQ
The P/E is 185% higher than the last 4 quarters average of 124.3
Royalty Pharma's EPS has shrunk by 93% YoY and by 91% QoQ

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
607.22M
Market cap
$21.51B
Enterprise value
$26.92B
Valuations
Price to earnings (P/E)
354.3
Price to book (P/B)
2.26
Price to sales (P/S)
6.94
EV/EBIT
116.64
EV/EBITDA
116.64
EV/Sales
12.03
Earnings
Revenue
$2.24B
EBIT
$230.79M
EBITDA
$230.79M
Free cash flow
$2.14B
Per share
EPS
$0.1
Free cash flow per share
$4.9
Book value per share
$15.69
Revenue per share
$5.11
TBVPS
$38.39
Balance sheet
Total assets
$16.81B
Total liabilities
$7.29B
Debt
$7.12B
Equity
$9.53B
Working capital
$1.39B
Liquidity
Debt to equity
0.75
Current ratio
2.19
Quick ratio
2.11
Net debt/EBITDA
23.42
Margins
EBITDA margin
10.3%
Gross margin
100%
Net margin
1.9%
Operating margin
13.7%
Efficiency
Return on assets
0.2%
Return on equity
0.4%
Return on invested capital
1%
Return on capital employed
1.5%
Return on sales
10.3%
Dividend
Dividend yield
2.17%
DPS
$0.77
Payout ratio
770%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
1.81%
1 week
2.28%
1 month
-2.61%
1 year
-8.02%
YTD
-10.35%
QTD
-10.35%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.24B
Gross profit
$2.24B
Operating income
$307.07M
Net income
$42.83M
Gross margin
100%
Net margin
1.9%
Royalty Pharma's net margin has shrunk by 93% YoY and by 92% QoQ
The net income has plunged by 93% YoY and by 92% from the previous quarter
The operating income has plunged by 79% YoY and by 67% from the previous quarter
The operating margin has dropped by 78% year-on-year and by 67% since the previous quarter

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
P/E
354.3
P/B
2.26
P/S
6.94
EV/EBIT
116.64
EV/EBITDA
116.64
EV/Sales
12.03
The P/E is 185% higher than the last 4 quarters average of 124.3
Royalty Pharma's EPS has shrunk by 93% YoY and by 91% QoQ
RPRX's equity is down by 9% since the previous quarter and by 7% year-on-year
RPRX's P/B is 6% below its last 4 quarters average of 2.4
The P/S is 11% below the last 4 quarters average of 7.8
The revenue has decreased by 2.3% YoY

Efficiency

How efficient is Royalty Pharma business performance
The ROA has plunged by 95% YoY and by 93% from the previous quarter
RPRX's ROE has plunged by 93% YoY and by 92% from the previous quarter
The ROIC has shrunk by 72% YoY and by 68% QoQ
Royalty Pharma's return on sales has shrunk by 70% YoY and by 67% QoQ

Dividends

What is RPRX's dividend history
DPS
$0.77
Dividend yield
2.17%
Payout ratio
770%
Recent dividends

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 131% more than its total liabilities
The company's quick ratio has shrunk by 87% YoY but it rose by 6% QoQ
The current ratio has dropped by 87% year-on-year but it has increased by 6% since the previous quarter
Royalty Pharma's debt is 25% lower than its equity
The debt to equity has increased by 10% QoQ and by 9% YoY
RPRX's equity is down by 9% since the previous quarter and by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.